333 related articles for article (PubMed ID: 23852369)
1. MEK drives cyclin D1 hyperelevation during geroconversion.
Leontieva OV; Demidenko ZN; Blagosklonny MV
Cell Death Differ; 2013 Sep; 20(9):1241-9. PubMed ID: 23852369
[TBL] [Abstract][Full Text] [Related]
2. CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.
Leontieva OV; Blagosklonny MV
Cell Cycle; 2013 Sep; 12(18):3063-9. PubMed ID: 23974099
[TBL] [Abstract][Full Text] [Related]
3. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
[TBL] [Abstract][Full Text] [Related]
4. S6K in geroconversion.
Leontieva OV; Demidenko ZN; Blagosklonny MV
Cell Cycle; 2013 Oct; 12(20):3249-52. PubMed ID: 24036549
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin, proliferation and geroconversion to senescence.
Blagosklonny MV
Cell Cycle; 2018; 17(24):2655-2665. PubMed ID: 30541374
[TBL] [Abstract][Full Text] [Related]
6. Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells.
Leontieva OV; Lenzo F; Demidenko ZN; Blagosklonny MV
Cell Cycle; 2012 Dec; 11(24):4642-9. PubMed ID: 23187803
[TBL] [Abstract][Full Text] [Related]
7. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts.
Stein GH; Drullinger LF; Soulard A; Dulić V
Mol Cell Biol; 1999 Mar; 19(3):2109-17. PubMed ID: 10022898
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia suppresses conversion from proliferative arrest to cellular senescence.
Leontieva OV; Natarajan V; Demidenko ZN; Burdelya LG; Gudkov AV; Blagosklonny MV
Proc Natl Acad Sci U S A; 2012 Aug; 109(33):13314-8. PubMed ID: 22847439
[TBL] [Abstract][Full Text] [Related]
9. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
[TBL] [Abstract][Full Text] [Related]
10. Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion.
Leontieva OV; Blagosklonny MV
Oncotarget; 2014 Dec; 5(24):12715-27. PubMed ID: 25587030
[TBL] [Abstract][Full Text] [Related]
11. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging.
Blagosklonny MV
Aging (Albany NY); 2012 Mar; 4(3):159-65. PubMed ID: 22394614
[TBL] [Abstract][Full Text] [Related]
12. Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).
Leontieva OV; Demidenko ZN; Blagosklonny MV
Oncotarget; 2015 Sep; 6(27):23238-48. PubMed ID: 26177051
[TBL] [Abstract][Full Text] [Related]
13. Growth stimulation leads to cellular senescence when the cell cycle is blocked.
Demidenko ZN; Blagosklonny MV
Cell Cycle; 2008 Nov; 7(21):3355-61. PubMed ID: 18948731
[TBL] [Abstract][Full Text] [Related]
14. Endothelial replicative senescence delayed by the inhibition of MTORC1 signaling involves MicroRNA-107.
Khor ES; Wong PF
Int J Biochem Cell Biol; 2018 Aug; 101():64-73. PubMed ID: 29857052
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence.
Demidenko ZN; Shtutman M; Blagosklonny MV
Cell Cycle; 2009 Jun; 8(12):1896-900. PubMed ID: 19478560
[TBL] [Abstract][Full Text] [Related]
16. Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program.
Leontieva OV; Demidenko ZN; Blagosklonny MV
Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8832-7. PubMed ID: 24889617
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin decelerates cellular senescence.
Demidenko ZN; Zubova SG; Bukreeva EI; Pospelov VA; Pospelova TV; Blagosklonny MV
Cell Cycle; 2009 Jun; 8(12):1888-95. PubMed ID: 19471117
[TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation.
Paternot S; Roger PP
Cancer Res; 2009 Jun; 69(11):4577-81. PubMed ID: 19458076
[TBL] [Abstract][Full Text] [Related]
19. RUNX3 regulates cell cycle-dependent chromatin dynamics by functioning as a pioneer factor of the restriction-point.
Lee JW; Kim DM; Jang JW; Park TG; Song SH; Lee YS; Chi XZ; Park IY; Hyun JW; Ito Y; Bae SC
Nat Commun; 2019 Apr; 10(1):1897. PubMed ID: 31015486
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism.
Wang R; Yu Z; Sunchu B; Shoaf J; Dang I; Zhao S; Caples K; Bradley L; Beaver LM; Ho E; Löhr CV; Perez VI
Aging Cell; 2017 Jun; 16(3):564-574. PubMed ID: 28371119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
